Results 11 to 20 of about 1,320,066 (287)

Chronic kidney disease (CKD) patients are exposed to more proton pump inhibitor (PPI)s compared to non-CKD patients. [PDF]

PLoS ONE, 2018
BACKGROUND:Proton pump inhibitor use is associated with incident chronic kidney disease, chronic kidney disease progression and end-stage renal disease.
Hee Jeong Lee, Haekyung Lee, Song Hee Oh, Joonbyung Park, Suyeon Park, Jin Seok Jeon, HyunJin Noh, Dong Cheol Han, Soon Hyo Kwon   +8 more
doaj   +1 more source

Abrupt-onset, profound erectile dysfunction in a healthy young man after initiating over-the-counter omeprazole: a case report

Journal of Medical Case Reports, 2021
Background Proton pump inhibitors are frequently used (and often overused) medications with adverse effects including vitamin B12 deficiency, Clostridium difficile colitis, and increased risk of chronic kidney disease.
Theodore W. Perry
doaj   +1 more source

Proton-Pump Inhibitors and Fragility Fractures in Vulnerable Older Patients [PDF]

, 2017
To the Editor: Proton Pump Inhibitors (PPIs) taken for ≥1 year have been linked to increased fragility fracture (FF) risk, prompting the US FDA to issue a related warning.
W Henley (16997595), W Hamilton (19248520), A Ble (21848018), JA Masoli (21848024), J Delgado (7769732), D Melzer (14728009), J Zirk-Sadowski (21848027), WD Strain (14423826)   +7 more
core   +6 more sources

Overprescribing proton pump inhibitors [PDF]

BMJ, 2008
Proton pump inhibitors are one of the most frequently prescribed classes of drug in the world because they combine a high level of efficacy with low toxicity. In 2006, expenditure on these drugs was £425m (€595m; $872m) in England1 and £7bn globally.2 Yet studies consistently show that proton pump inhibitors are being overprescribed worldwide in both ...
Ian, Forgacs, Aathavan, Loganayagam
openaire   +2 more sources

Proton-pump inhibitors and risk of renal disease [PDF]

Journal of Nephropharmacology, 2017
Proton pump inhibitors (PPIs) are one group of drugs that inhibit gastric acid secretion by binding irreversibly to the gastric proton pump to the gastric proton pump.
Mahrang Hedaiaty, Mohammad Reza Tamadon, Armin Amiri, Leila Mahmoodnia   +3 more
doaj   +1 more source

Proton pump inhibitors and gastroenteritis [PDF]

European Journal of Epidemiology, 2016
An association between proton pump inhibitor (PPI) therapy and bacterial gastroenteritis has been suggested as well as contradicted. The aim of this study was to examine the association between the use of PPIs and occurrence of bacterial gastroenteritis in the prospective Rotterdam Study.
Hassing, Robert-Jan, Verbon, Annelies, Visser, H, Hofman, Bert, Stricker, Bruno   +4 more
openaire   +2 more sources

Association between proton pump inhibitor therapy and clostridium difficile infection: a contemporary systematic review and meta-analysis. [PDF]

, 2012
Introduction Emerging epidemiological evidence suggests that proton pump inhibitor (PPI) acid-suppression therapy is associated with an increased risk of Clostridium difficile infection (CDI).
Sutton, AJ, Imad M. Tleyjeh (104252), Tannir Mohamad Al, Alex J Sutton, AlGhamdi, M, Muhammad Riaz (104236), Bin Abdulhak, AA, Ibrahim Talal, Mushabab AlGhamdi (112556), Baddour, LM, Alasmari Faisal A., A. A. Bin Abdulhak (7656569), Abed Allehibi, Talal Ibrahim (112568), Allehibi, A., Alasmari, FA, Faisal A. Alasmari (112549), F. A. Alasmari (7656575), A. R. Khan (3951662), AlGhamdi Mushabab, A. AlLehibi (7656593), Khan, AR, Al Tannir, M, Tleyjeh, IM, I. M. Tleyjeh (7656566), AlGhamdi, M., Abed AlLehibi (112573), Khan, A. R., Alex J. Sutton (112577), Garbati Musa A., L. M. Baddour (7656596), Aref A Bin Abdulhak, M. A. Garbati (7656578), M. Al Tannir (7656584), Bin Abdulhak, A. A., M. AlGhamdi (7656581), Erwin, P. J., Imad M Tleyjeh, Khan Abdur Rahman, Tleyjeh, I. M., Patricia J Erwin, T. Ibrahim (7656590), Muhammad Riaz, Abdur Rahman Khan (104234), Garbati, MA, Allehibi, A, Bin Abdulhak Aref A., Erwin, PJ, Sutton Alex J., M. Riaz (7656572), Riaz Muhammad, Musa A Garbati, Alasmari, F. A., Patricia J. Erwin (104246), Talal Ibrahim, Abdur Rahman Khan, Ibrahim, T., Mushabab AlGhamdi, A. J. Sutton (7648487), Faisal A Alasmari, Ibrahim, T, Mohamad Al Tannir (112562), Mohamad Al Tannir, Erwin Patricia J., Larry M Baddour, Baddour Larry M., Al Tannir, M., P. J. Erwin (7656587), Aref A. Bin Abdulhak (104239), Garbati, M. A., Larry M. Baddour (104249), Riaz, Muhammad, Riaz, M, Tleyjeh Imad M., Baddour, L. M., Sutton, A. J., Musa A. Garbati (104244), AlLehibi Abed   +77 more
core   +1 more source

Risk of Bacterial Infection from Proton Pump Inhibitor Use

The Korean Journal of Helicobacter and Upper Gastrointestinal Research, 2017
Currently, proton pump inhibitors are used in a wide range of patients with gastroesophageal reflux disease, peptic ulcer, and upper gastrointestinal symptoms such as dyspepsia.
Sung Soo Kim, Yunju Jo, Seun Ja Park, Jeong Seop Moon, Dong Ho Lee, Jae Jun Kim, Yong Chan Lee, Ethics and Education Committee of Korean College of Helicobacter and Upper Gastrointestinal Research   +7 more
doaj   +1 more source

Association of Histamine-2 Blockers and Proton-Pump Inhibitors With Delirium Development in Critically Ill Adults: A Retrospective Cohort Study

Critical Care Explorations, 2021
OBJECTIVES:. Histamine-2 receptor antagonists are commonly administered for stress ulcer prophylaxis in critically ill adults and may be associated with delirium development.
Ami Shiddapur, BS, Christine E. Kistler, MD, MASc, Jan Busby-Whitehead, MD, C. Adrian Austin, MD, MSCR   +3 more
doaj   +1 more source

Overuse of proton pump inhibitors [PDF]

Polish Archives of Internal Medicine, 2015
Proton pump inhibitors (PPIs) are currently the most effective drugs inhibiting hydrochloric acid secretion. They have replaced histamine type 2 receptor antagonists in the majority of clinical indications, for example, functional dyspepsia, gastroesophageal reflux disease, or drug‑induced upper gastrointestinal tract injury.
Dorota, Ksiądzyna, Adam, Szeląg, Leszek, Paradowski   +2 more
openaire   +2 more sources